News and Announcements
QBiotics Presents its Veterinary Cancer Compound
- Published June 01, 2016 4:33PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
1st June 2016, Life Scientist
Australian life sciences company QBiotics outlined the latest clinical developments in its cancer compound, EBC-46, to an audience of veterinary cancer experts last week.
Speaking at The World Veterinary Cancer Congress in Brazil, QBiotics CEO Dr Victoria Gordon and Chief Veterinary Officer Dr Stewart Lowden showcased the latest clinical research results from a range of studies. The trials underpin the efficacy of EBC-46 as an intratumoral treatment for cutaneous and subcutaneous mast cell tumours and soft tissue sarcomas in dogs.
EBC-46 is a natural product isolated from the seed of Australian rainforest shrub Fontainea picrosperma. A ready-to-use injectable solution, the drug works by initiating tumour necrosis directly and by tumour blood vessel destruction, followed by rapid wound healing.
“EBC-46 is a signalling molecule which turns on the animal’s own immune system to destroy the tumour,” explained Dr Gordon. “It also has the advantage of being easy to administer, causes minimal trauma to the animals during treatment and has no significant negative side effects.
“Tumour destruction is rapid [and] wounds heal without the need for intervention, such as antibiotics and lotions, and with minimal scarring.”
To view the full article, please click on the button below.